# Hypothalamic Obesity FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypothalamic-obesity

> 2 upcoming FDA catalysts in hypothalamic Obesity: bivamelagon (RYTM) on Apr to Jul 2028 (topline data readout); bivamelagon (RYTM) on April 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 9, 2026 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443)) |
| late 2026 | [Bivamelagon trial start](https://sec-api.dev/pdufa/bivamelagon) | RYTM | hypothalamic obesity | scheduled | "Following a highly constructive end-of-phase-2 meeting with the FDA where we shared encouraging open-label extension data focused on our oral MC4R agonist bivamelagon, we remain on track to initiate a Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| October 30, 2026 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443?tab=results)) |
| Apr to Jul 2028 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | scheduled | "NCT07156578 (A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-04-15 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156578)) |
| April 2028 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | scheduled | "NCT07156578 (A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-04-15 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156578)) |

## Drugs

- [Bivamelagon](https://sec-api.dev/pdufa/bivamelagon) (RYTM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypothalamic-obesity.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypothalamic Obesity FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypothalamic-obesity

```bibtex
@misc{secapidev_indications_hypothalamic_obesity_20261116,
  title        = {Hypothalamic Obesity FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypothalamic-obesity}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypothalamic_obesity_20261116","title":"Hypothalamic Obesity FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypothalamic-obesity","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
